Y-mAbs Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a YMAB research report →
About the company
Y-mAbs Therapeutics, Inc. is a biopharmaceutical firm already generating revenue, dedicated to discovering, advancing, and selling innovative antibody-derived therapies specifically designed to combat cancer within the United States. Its flagship product, DANYELZA, is a monoclonal antibody administered alongside granulocyte-macrophage colony-stimulating factor, targeting high-risk neuroblastoma in children when the disease has returned or proven resistant to prior treatments.
- CEO
- Michael Rossi
- IPO
- 2018
- Employees
- 104
- HQ
- Princeton, NY, US
Price Chart
- Market Cap
- $391.22M
- P/E
- -44.96
- P/S
- 9.68
- P/B
- 4.46
- EV/EBITDA
- -40.01
- Div Yield
- 0.00%
- Gross Margin
- 85.99%
- Op Margin
- -30.05%
- Net Margin
- -20.86%
- ROE
- -9.53%
- ROIC
- -12.75%
- Revenue
- $87.69M · 3.38%
- Net Income
- $-29,666,000 · -38.45%
- EPS
- $-0.67 · -36.73%
- Op Income
- $-31,201,000
- FCF YoY
- 42.30%
- 52W High
- $16.11
- 52W Low
- $3.55
- 50D MA
- $6.84
- 200D MA
- $6.12
- Beta
- 0.53
- Avg Volume
- 905.07K
Get TickerSpark's AI analysis on YMAB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 16, 25 | Hamill Laura | other | 5,825 |
| Sep 16, 25 | Hamill Laura | sell | 27,000 |
| Sep 16, 25 | Hamill Laura | sell | 25,080 |
| Sep 16, 25 | Hamill Laura | sell | 11,000 |
| Sep 16, 25 | Hamill Laura | sell | 16,000 |
| Sep 16, 25 | Hamill Laura | sell | 14,545 |
| Sep 16, 25 | Hamill Laura | sell | 33,450 |
| Sep 16, 25 | Hamill Laura | sell | 13,950 |
| Sep 16, 25 | WG Biotech ApS | other | 4,559,233 |
| Sep 16, 25 | Gentilcore Douglas J | sell | 142,600 |
Our YMAB coverage
Recent articles, reports, and earnings notes.
No research on YMAB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate YMAB report →Similar companies
Peers in the same neighborhood.